The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer

R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard, R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard

Abstract

Aim: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy.

Methods: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed. Women were assessed for premature ovarian insufficiency (POI: amenorrhoea with elevated follicle-stimulating hormone (FSH)) at 24 months after diagnosis. The accuracy of AMH for the diagnosis of POI and its prediction from measurement at the end of chemotherapy was calculated.

Results: AMH below the level of detection showed good diagnostic accuracy for POI at 24 months (n = 73) with receiver operating characteristic (ROC) area under the curve of 0.86, sensitivity 1.0 and specificity 0.73 at the assay limit of detection. In women aged >40 at diagnosis who did not receive goserelin, AMH measured at end of chemotherapy also gave good prediction of POI at 24 months (area under the curve (AUC) 0.89 95% CI 0.75-1.0, n = 32), with sensitivity 0.91, specificity 0.82, diagnostic odds ratio (DOR) 42.8. FSH gave slightly lower AUC, and specificity was low at 0.55. Age but not tamoxifen impacted on AMH levels.

Conclusion: Using this sensitive AMH assay, the finding of an undetectable AMH level in women aged >40 at the end of chemotherapy for eBC gave a good prediction that ovarian function would not return. This may allow alterations in post-chemotherapy endocrine management.

Keywords: Breast cancer; Hormone sensitive; Menopause; Ovarian function.

Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Serum oestradiol (A), FSH (B) and AMH (C) at pre-treatment baseline, end of treatment (EOT) and at 12 and 24 months after diagnosis, by POI at 24 months. Data from all women from the OPTION trial. Red, women without POI; blue: women with POI (amenorrhoea plus FSH >25IL/L at 24 months). N = 96 and 28 respectively; median ±95% confidence intervals.
Fig. 2
Fig. 2
Serum oestradiol (A), FSH (B) and AMH (C) at end of treatment (EOT) and at 12 and 24 months after diagnosis in women aged ≤40 (open bars) versus >40 years (filled bars); n = 62 and 81, median ± 95% confidence intervals.
Fig. 3
Fig. 3
ROC curve analysis of AMH (red) and FSH (blue) at 24 months for (A) analysis of amenorrhoea versus ongoing menses (n = 22 and 51 respectively); (B) for diagnosis of POI versus not POI (n = 14 and 59 respectively). Data from all women in OPTION included.
Fig. 4
Fig. 4
ROC curve analysis of (A) AMH (red) and FSH (blue) at end of treatment for prediction of POI versus not POI at 24 months (n = 23 and 45 respectively) for all women in the OPTION control group. (B) AMH (red) and FSH (blue) serum concentrations at end of treatment for prediction of POI versus not POI at 24 months for women aged >40 years in the control group in OPTION (n = 21 and 11 respectively). (C) Oestradiol concentrations at 12 and 24 months in women with undetectable AMH (blue) and detectable AMH (red) at the end of chemotherapy.

References

    1. Early Breast Cancer Trialists' Collaborative G, Dowsett M., Forbes J.F., Bradley R., Ingle J., Aihara T. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
    1. Dowsett M., Stein R.C., Coombes R.C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1992;43(1–3):155–159.
    1. Pagani O., Regan M.M., Walley B.A., Fleming G.F., Colleoni M., Lang I. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–118.
    1. Francis P.A., Regan M.M., Fleming G.F., Lang I., Ciruelos E., Bellet M. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–446.
    1. Bernhard J., Luo W., Ribi K., Colleoni M., Burstein H.J., Tondini C. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–858.
    1. Petrek J.A., Naughton M.J., Case L.D., Paskett E.D., Naftalis E.Z., Singletary S.E. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045–1051.
    1. Jacobson M.H., Mertens A.C., Spencer J.B., Manatunga A.K., Howards P.P. Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. Fertil Steril. 2016;105(3):765–772e4.
    1. Smith I.E., Dowsett M., Yap Y.S., Walsh G., Lonning P.E., Santen R.J. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24(16):2444–2447.
    1. Anderson R.A., Cameron D.A. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96(5):1336–1343.
    1. Su H.C., Haunschild C., Chung K., Komrokian S., Boles S., Sammel M.D. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014;120(23):3691–3698.
    1. Ruddy K.J., O'Neill A., Miller K.D., Schneider B.P., Baker E., Sparano J.A. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–597.
    1. Gracia C.R., Sammel M.D., Freeman E., Prewitt M., Carlson C., Ray A. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012;97(1):134–140e1.
    1. Vriens I.J., De Bie A.J., Aarts M.J., de Boer M., van Hellemond I.E., Roijen J.H. The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget. 2017;8(7):11372–11379.
    1. Dewailly D., Andersen C.Y., Balen A., Broekmans F., Dilaver N., Fanchin R. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–385.
    1. Anderson R.A., Themmen A.P.N., Al Qahtani A., Groome N.P., Cameron D.A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21(10):2583–2592.
    1. Decanter C., Morschhauser F., Pigny P., Lefebvre C., Gallo C., Dewailly D. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010;20(2):280–285.
    1. Partridge A.H., Ruddy K.J., Gelber S., Schapira L., Abusief M., Meyer M. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94(2):638–644.
    1. Su H.I., Sammel M.D., Green J., Velders L., Stankiewicz C., Matro J. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116(3):592–599.
    1. Dillon K.E., Sammel M.D., Prewitt M., Ginsberg J.P., Walker D., Mersereau J.E. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99:477–483.
    1. Sowers M.R., Eyvazzadeh A.D., McConnell D., Yosef M., Jannausch M.L., Zhang D. Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–3483.
    1. Anderson R.A., Anckaert E., Bosch E., Dewailly D., Dunlop C.E., Fehr D. Prospective study into the value of the automated Elecsys antimullerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril. 2015;103(4):1074–1080e4.
    1. Chai J., Howie A.F., Cameron D.A., Anderson R.A. A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2014;50(14):2367–2374.
    1. Leonard R., Adamson D., Bertelli G., Mansi J., Yellowlees A., Dunlop J. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811–1816.
    1. ESHRE Guideline Group on POI, Webber L., Davies M., Anderson R., Bartlett J., Braat D. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937.
    1. Fischer J.E., Bachmann L.M., Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29(7):1043–1051.
    1. Su H.I., Chung K., Sammel M.D., Gracia C.R., DeMichele A. Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors. Fertil Steril. 2011;95(5):1857–1859.
    1. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168.
    1. Torino F., Barnabei A., De Vecchis L., Sini V., Schittulli F., Marchetti P. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol. 2014;89(1):27–42.
    1. Krekow L.K., Hellerstedt B.A., Collea R.P., Papish S., Diggikar S.M., Resta R. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol. 2016;34(14):1594–1600.
    1. Anderson R.A., Cameron D.A. Assessment of the effect of chemotherapy on ovarian function in women with breast cancer. J Clin Oncol. 2007;25(2):1630–1631.
    1. Dezellus A., Barriere P., Campone M., Lemanski C., Vanlemmens L., Mignot L. Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017;79:72–80.
    1. van Hellemond I.E.G., Vriens I.J.H., Peer P.G.M., Swinkels A.C.P., Smorenburg C.H., Seynaeve C.M. Ovarian function recovery during anastrozole in breast cancer patients with chemotherapy-induced ovarian function failure. JNCI JNatl Cancer Inst. 2017;109(12) djx074-djx074.
    1. Anderson R.A., Rosendahl M., Kelsey T.W., Cameron D.A. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. 2013;49(16):3404–3411.
    1. Hamy A.S., Porcher R., Eskenazi S., Cuvier C., Giacchetti S., Coussy F. Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies. Reprod Biomed Online. 2016;32(3):299–307.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa